2024 / 05

Next Paper
DOI: 10.24075/brsmu.2024.043

ORIGINAL RESEARCH

LoRI, a new recombinant RNase inhibitor for in vitro applications

Sukhov DA1,2,3, Kholoshenko IV1,4, Petrova TV1, Romanenko GA1,2, Myshkin MYu3, Kost VYu3, Trofimov DYu1, Usman NYu5, Barsova EV3,5
About authors

1 DNA-Technology LLC, 117587, Moscow, Russia

2 MIREA — Russian Technological University, Moscow, Russia

3 Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia

4 Bauman Moscow State Technical University, Moscow, Russia

5 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Natalia Yu. Usman
Ostrovityanova 1/1, Moscow, 117997, Russia; ur.relbmar@namsu_n

About paper

Funding: The study was funded by DNA-Technology LLC.

Author contribution: Sukhov DA, Romanenko GA — protein engineering, expression and purification; Kholoshenko IV, Petrova TV — product characterization, writing; Myshkin MYu — protein structure analysis; Kost VYu — study design; Trofimov DYu — project supervision; Usman NYu — writing; Barsova EV — project coordination, writing.

Received: 2024-09-02 Accepted: 2024-10-09 Published online: 2024-10-28
|
  1. Thomas SP, Kim E, Kim JS, Raines RT. Knockout of the ribonuclease inhibitorgGene leaves human cells vulnerable to secretory ribonucleases. Biochemistry. 2016; 55 (46): 6359–62. DOI: 10.1021/acs.biochem.6b01003.
  2. Abel RL, Haigis MC, Park C, Raines RT. Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein. Anal Biochem. 2002; 306 (1): 100–07. DOI: 10.1006/abio.2002.5678.
  3. Lee FS, Shapiro R, Vallee BL. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor [published correction appears in Biochemistry 1989 Mar 7; 28 (5): 2354]. Biochemistry. 1989; 28 (1): 225–30. DOI: 10.1021/bi00427a031.
  4. Nishibata Y, Koshimoto S, Ogaki K, Ishikawa E, Wada K, Yoshinari M, Ishizu A. RNase in the saliva can affect the detection of severe acute respiratory syndrome coronavirus 2 by real-time one-step polymerase chain reaction using saliva samples. Pathol Res Pract. 2021; 220: 153381. DOI: 10.1016/j.prp.2021.153381.
  5. Šiurkus J, Neubauer P. Heterologous production of active ribonuclease inhibitor in Escherichia coli by redox state control and chaperonin coexpression. Microb Cell Fact. 2011; 10: 65. DOI: 10.1186/1475-2859-10-65.
  6. Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2013; 18 (10): 1165–207. DOI: 10.1089/ars.2011.4322.
  7. LaVallie ER, Lu Z, Diblasio-Smith EA, Collins-Racie LA, McCoy JM. Thioredoxin as a fusion partner for production of soluble recombinant proteins in Escherichia coli. Methods Enzymol. 2000; 326: 322–40. DOI: 10.1016/s0076-6879(00)26063-1.
  8. Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024; 630: 493–500 DOI: 10.1038/s41586-024-07487-w.
  9. Kyratsous CA, Silverstein SJ, DeLong CR, Panagiotidis CA. Chaperone-fusion expression plasmid vectors for improved solubility of recombinant proteins in Escherichia coli. Gene. 2009; 440 (1–2): 9–15. DOI: 10.1016/j.gene.2009.03.011.
  10. Kobe B, Deisenhofer J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature. 1995; 374 (6518): 183–6. DOI: 10.1038/374183a0.
  11. Dixon M, Webb EC. Enzymes. 2nd Edition. New York: Academic Press, 1964.
  12. Fominaya JM, Hofsteenge J. Inactivation of ribonuclease inhibitor by thiol-disulfide exchange. J Biol Chem. 1992; 267 (34): 24655–60.
  13. Klink TA, Vicentini AM, Hofsteenge J, Raines RT. High-level soluble production and characterization of porcine ribonuclease inhibitor. Protein Expr Purif. 2001; 22 (2): 174–9. DOI: 10.1006/prep.2001.1422.
  14. Dickson KA, Haigis MC, Raines RT. Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol. 2005; 80: 349–74. DOI: 10.1016/S0079-6603(05)80009-1.